162 related articles for article (PubMed ID: 32723196)
1. Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma.
Abudayyeh A; Lin H; Mamlouk O; Abdelrahim M; Saliba R; Rondon G; Martinez CS; Delgado R; Page V; Rajasekaran A; Sanders PW; Qazilbash M
Leuk Lymphoma; 2020 Dec; 61(13):3101-3111. PubMed ID: 32723196
[TBL] [Abstract][Full Text] [Related]
2. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study.
Antlanger M; Dust T; Reiter T; Böhm A; Lamm WW; Gornicec M; Willenbacher E; Nachbaur D; Weger R; Rabitsch W; Rasoul-Rockenschaub S; Worel N; Lechner D; Greinix H; Keil F; Gisslinger H; Agis H; Krauth MT
BMC Cancer; 2018 Oct; 18(1):1008. PubMed ID: 30342509
[TBL] [Abstract][Full Text] [Related]
3. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
4. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
5. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
7. [Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results].
Sui WW; Zou DH; An G; Yi SH; Deng SH; Huang WY; Wang TY; Li J; Liu H; Fu MW; Lyu R; Liu W; Xu Y; Li ZJ; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):499-504. PubMed ID: 28655093
[No Abstract] [Full Text] [Related]
8. Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma.
Zhang BL; Zhou J; Lin QD; Liu YZ; Zhang YL; Gui RR; Song YP; Fang BJ
Artif Organs; 2019 Oct; 43(10):1028-1034. PubMed ID: 30972806
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma.
Parmar H; Al Saleh AS; Visram A; Warsame R; Kourelis T; Gonsalves W; Dingli D; Muchtar E; Hayman S; Kapoor P; Buadi F; Dispenzieri A; Lacy M; Gertz M; Kumar S
Transplant Cell Ther; 2021 Apr; 27(4):309.e1-309.e5. PubMed ID: 33836869
[TBL] [Abstract][Full Text] [Related]
10. Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On
Cho HJ; Baek DW; Kim JH; Lee J; Chung YK; Jung SH; Song GY; Ahn SY; Ahn JS; Yang DH; Lee JJ; Kim HJ; Hong CM; Jeong SY; Min JJ; Sohn SK; Moon JH
Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):113-120. PubMed ID: 34598908
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option.
Lazana I; Floro L; Christmas T; Shah S; Bramham K; Cuthill K; Bassett P; Schey S; Kazmi M; Potter V; Pagliuca A; Streetly M; Benjamin R
Bone Marrow Transplant; 2022 Jun; 57(6):959-965. PubMed ID: 35413986
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
13. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
Hashmi H; Atrash S; Jain J; Khasawneh G; Mohan M; Mahmoudjafari Z; Cui W; McGuirk J; Shune L; Ahmed N; Abdallah AO
Transplant Cell Ther; 2023 Apr; 29(4):262.e1-262.e6. PubMed ID: 36682468
[TBL] [Abstract][Full Text] [Related]
14. Response and Dynamics of Renal Function in Transplantation-Eligible Multiple Myeloma Patients Treated with a Novel Agent: The CAREMM-2201 Study.
Kim Y; Park SS; Jeon YW; Yahng SA; Shin SH; Min CK;
Transplant Cell Ther; 2023 Jan; 29(1):55.e1-55.e9. PubMed ID: 36202336
[TBL] [Abstract][Full Text] [Related]
15. [Retrospective analysis on therapeutic effect of autologous hematopoietic stem cell transplantation in multiple myeloma patients].
Wang J; Fu CC; Wu DP; Sun AN; Xue SL; Xin X; Hu XH; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Han Y; Ma X; He GS; Chang WR; Chen SN
Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(2):114-8. PubMed ID: 23648347
[TBL] [Abstract][Full Text] [Related]
16. Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation.
Geng C; Zhou H; Wang H; Li Y; Leng Y; Zhang Z; Jian Y; Yang G; Chen W
BMC Cancer; 2022 Dec; 22(1):1349. PubMed ID: 36564753
[TBL] [Abstract][Full Text] [Related]
17. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation.
Mikulski D; Kościelny K; Nowicki M; Wawrzyniak E; Kalwas M; Kowalik M; Pryt M; Sęczkowska E; Świątek A; Wierzbowska A; Fendler W
Leuk Lymphoma; 2023 Jan; 64(1):98-106. PubMed ID: 36318865
[TBL] [Abstract][Full Text] [Related]
19. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
Ho PJ; Moore EM; McQuilten ZK; Wellard C; Bergin K; Augustson B; Blacklock H; Harrison SJ; Horvath N; King T; Mollee P; Quach H; Reid C; Rosengarten B; Walker P; Wood EM; Spencer A
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e415-e424. PubMed ID: 31208889
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome.
Kumar L; Ramavath D; Kataria B; Tiwari A; Raj A; Chellapuram SK; Mookerjee A; Sahoo RK; Malik PS; Sharma A; Gupta R; Sharma OD; Biswas A; Kumar R; Thulkar S;
Indian J Med Res; 2019 Jun; 149(6):730-739. PubMed ID: 31496525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
